Tumor-Specific CD4+ T Cells Render the Tumor Environment Permissive for Infiltration by Low-Avidity CD8+ T Cells

Abstract

CD4+ T cells enhance tumor destruction by CD8+ T cells. One benefit that underlies CD4+ T cell help is enhanced clonal expansion of newly activated CD8+ cells. In addition, tumor-specific CD4+ help is also associated with the accumulation of greater numbers of CD8+ T cells within the tumor. Whether this too is attributable to the effects of help delivered to the CD8+ cells during priming within secondary lymphoid tissues, or alternatively is due to the action of CD4+ cells within the tumor environment has not been examined. In this study, we have evaluated separately the benefits of CD4+ T cell help accrued during priming of tumor-specific CD8+ T cells with a vaccine, as opposed to the benefits delivered by the presence of cognate CD4+ cells within the tumor. The presence of CD4+ T cell help during priming increased clonal expansion of tumor-specific CD8+ T cells in secondary lymphoid tissue; however, CD8+ T cells that have low avidity for tumor Ag were inefficient in tumor invasion. CD4+ T cells that recognized tumor Ag were required to facilitate accumulation of CD8+ T cells within the tumor and enhance tumor lysis during the acute phase of the response. These experiments highlight the ability of tumor-specific CD4+ T cells to render the tumor microenvironment receptive for CD8+ T cell immunotherapy, by facilitating the accumulation of all activated CD8+ T cells, including low-avidity tumor-specific and noncognate cells.

Cancer vaccines: Uses of HLA transgenic mice compared to genetically modified mice

“…Although, it is now accepted that CD4 + T cells play a major role in initiating and maintaining CD8 + immune responses (22) as well as helping in the development of memory CD8 + T cells (23). More recently, Sherman's group were able to demonstrate yet another role to these cells, that of facilitating entry of CD8 + T cells into the tumor microenvironment (24). Only a limited number of T-helper epitopes have been identified to date (25,26) /IE 0/0 mice we have successfully identified four novel class-II derived peptides derived from p53, PAP and HAGE proteins (5,6,30).…”

Using Autoimmunity To Inform Tumor Immunity

“…However, just as we had found in our studies of CD8 T cell tolerance in InsHA mice, such tolerance could be overcome and tumor cells could be eradicated if we also supplied tumor-specific CD4 cells. We found the CD4 helper cells needed to be present within the tumor microenvironment to be effective in promoting tumor killing by the CD8 cells (32). Successful tumor eradication required production by the CD4 cells of both IFN-g and IL-2.…”

Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine

“…31 One explanation could be related to the inefficiency of non-tumor specific CD4 + T cells to guide effector CD8 + T cells within the tumor as recently demonstrated by Sherman L and colleagues. 32,33 Indeed, CD8…”